Jesse Polansky, a former Pfizer executive, filed a lawsuit against the company accusing it of misleading physicians about its cholesterol drug Lipitor through its use of educational programs and product labeling as well as manipulating federal cholesterol regulations in order to boost sales of the drug. Mr. Polansky specifically claimed sales of Lipitor increased 18 percent because Pfizer had illegally marketed off-label use of the drug, causing false claims to be submitted to federal healthcare programs.
Mr. Polansky also accuses Pfizer of being involved in an alleged kickback scheme, according to the report. The report does not disclose any details about the alleged kickbacks scheme or what off-label uses were promoted.
Read the AboutLawsuits report about the Pfizer’s alleged fraud.
Read other coverage about Pfizer:
– Justice Department Files to Intervene in Whistleblower Kickback Case Against Pfizer
– 5 Antikickback Cases Making Headlines
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
